Table 2.
Base case analysis results from health system perspective of Prophylactic Emicizumab vs bypassing agents for severe haemophilia A patients with inhibitors in India.
| Treatment | Cost of treatment | Incremental cost | Total bleeding events | Bleeding events averted | QALYs gained | Incremental utility | ICUR |
|---|---|---|---|---|---|---|---|
| Prophylactic Emicizumab | 295,209.7 USD (21,826,624.4 INR) | – | 42 | – | 7.18 | – | – |
| On-demand Recombinant Factor VIIa | 920394.6 USD (68,050,295.1 INR) | – | 221 | – | 6.45 | – | – |
| On-demand APCC | 427718.9 (31,623,824.6 INR) | – | 227 | – | 6.55 | – | – |
| Prophylactic Emicizumab vs Recombinant factor VIIa | – | −625,185 USD (−46,223,678.2 INR) | – | 179 | – | 0.732 | −853,573 USD (−63,109,773 INR) |
| Prophylactic Emicizumab vs APCC | – | −132509.2 USD (−9,797,200.2 INR) | – | 185 | – | 0.626 | −211,675 USD (−15,650,403 INR) |
APCC - Factor eight inhibitor bypass activity (activated prothrombin complex concentrates); ICU-Intensive Care Unit; INR – Indian Rupees; SAE – Serious Adverse Events; USD – United States Dollars; QALY-Quality adjusted life years.